Kodiak Sciences Inc.

NASDAQ:KOD

Biotechnology

Healthcare
$97.81 -0.08%

-$0.03 today

Market cap
$6.40B
Beta
2.21
P/E (TTM)
-9.6
EPS (TTM)
-$3.73
52W Low $3.43High $47.84

Volume 0.74M

Average 1.10M

KOD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Kodiak Sciences Inc.NASDAQ: KOD

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income grows, but more slowly than its trailing trend

Q3 FY2026 net income of $66.22M (cash outflow) rose 7.8% year over year, behind the +13.5% change in trailing-twelve-month net income. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$196.36M (-14.6%) for the fiscal year ending Dec 2026, a slowdown from the +30.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$66.22M+0.9% QoQ
Last fiscal yearDec 2025
-$229.97M+30.5% YoY
LTMSep 2026
-$246.76M+13.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.8%-1.8%-9.5 pp
1 year+30.5%-14.6%-45.1 pp
3-year CAGR-11.7%-33.7%-22.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(229.97M) USD
Year-over-year change
-30.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How KOD compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.5% is the 5th highest of 10, against a peer median of -2.9%.
  • Over three fiscal years its annual growth of -11.7% compares with a peer median of +20.3%.
KOD Competitors
Net Income for KOD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$4.33B USD-2.9%+1.3%27.9%
OCULOcular Therapeutix, Inc.LTM Mar 2026$290.5M USD+50.7%+55.3%558.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$271.6M USD+85.0%+31.4%3566.6%
KODKodiak Sciences Inc.LTM Sep 2026$246.76M USD+13.5%-11.7%—
BLCOBausch + Lomb CorporationLTM Jun 2026$167M USD-36.5%—3.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M USD-8.8%+9.2%182.3%
OCSOculis Holding AGLTM Mar 2026CHF 94.54M CHF-8.3%+34.7%18758.0%
OCGNOcugen, Inc.LTM Mar 2026$71.67M USD+24.7%-7.9%1605.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M USD-388.6%-1.9%18297.5%
BLTEBelite Bio, IncLTM Jun 2026$102.36K USD+140.6%+83.1%—
Peer median (excluding KOD) —-2.9%+20.3%1081.7%

Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Depreciation & Amortization8.71M11M25.95M26.71M26.32M
Deferred Income Tax00000
Stock-Based Compensation61.39M106.03M88.56M60.21M58.86M
Change in Working Capital14.43M11.96M(7.36M)(28.39M)6.85M
Accounts Receivables00000
Inventory00000
Accounts Payables(2.09M)1.66M5.6M(9.69M)8.07M
Other Working Capital16.52M10.3M(12.95M)(18.69M)(1.22M)
Other Non-Cash Items198K(1.63M)(840K)355K1.93M
Operating Cash Flow(182.27M)(206.46M)(154.18M)(117.32M)(136.01M)
Capital Expenditures(63.3M)(47.36M)(41.43M)(400K)(506K)
Acquisitions (Net)00(290.65K)00
Purchases of Investments0(427.77M)(49.35M)(355K)0
Sales of Investments24.5M138M340M00
Other Investing Activities0616K290.65K00
Investing Cash Flow(38.8M)(336.51M)249.23M(755K)(506K)
Debt Repayment00000
Common Stock Issued8.23M1.94M242K501K178.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(45K)(49K)(211K)00
Financing Cash Flow8.18M1.9M31K501K178.3M
Effect of Forex Changes00000
Net Change in Cash(212.89M)(541.08M)95.07M(117.57M)41.79M
Free Cash Flow(245.57M)(253.82M)(195.61M)(117.72M)(136.51M)

Kodiak Sciences Inc.

NASDAQ:KOD

Intrinsic Alpha fair value

Locked

Current Price

$97.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.